Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05921812Recruiting
Blood tests for lymphoma using small RNA markers
This study looks at tiny blood molecules called microRNAs to see if they can help diagnose non-Hodgkin's lymphoma. If you are newly diagnosed and have no other cancers, your blood test results may be compared to known patterns to improve diagnosis.
SohagAges 18–75 - NCT05929222RecruitingPhase 3
Radiation with or without an antibody for early follicular lymphoma
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
Sassuolo, Modena (MO)Ages 18 years+ - NCT05929612RecruitingPhase 2
Low-dose targeted radiation alone for marginal zone lymphoma
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
Houston, TexasAges 18 years+ - NCT05934513RecruitingPhase 1/Phase 2
Study drug GFH009 for relapsed lymphoma after prior treatments
This early-phase study tests GFH009 (given alone) in adults with peripheral T-cell lymphoma that has come back or not responded. It may help shrink lymphoma in people who have already tried several other treatments.
Guanzhou, GuangdongAges 18–75 - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05949944RecruitingPhase 1/Phase 2
Testing linperlisib plus CHOP for untreated peripheral T-cell lymphoma
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
Guangzhou, GuangdongAges 18 years+ - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05959694RecruitingPhase 1/Phase 2
Study drug TQB3909 for CLL/SLL that keeps coming back
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Anqing, AnhuiAges 18–75 - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT05982223Recruiting
Integrative medicine for lymphoma survivors in early remission
This study explores how integrative medicine (such as nutrition, mind-body practices, or supplements) might help people recover and improve well-being after finishing lymphoma treatment. It is for patients who are in remission for less than one year.
HaifaAges 18 years+ - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT05991388RecruitingPhase 2/Phase 3
New treatments for children with relapsed B-NHL
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
Sydney, New South WalesAges Up to 25 years - NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT06002828Recruiting
Social and genetic factors in young adult cancer survivors
This study looks at how social and genetic factors affect the health and quality of life of young adults who have survived Hodgkin or non-Hodgkin lymphoma. It may help doctors better support survivors after treatment.
Anchorage, AlaskaAges 18 years+ - NCT06008691Recruiting
Study of newer antibodies for B-cell lymphoma in Italy
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Viagrande, CataniaAges 18 years+ - NCT06026488Recruiting
Study of DLBCL by genetic subtype
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06029309RecruitingPhase 1/Phase 2
Zanubrutinib and tafasitamab for mantle cell lymphoma
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Miami, FloridaAges 18 years+ - NCT06043323RecruitingPhase 2
CAR T cells plus radiation for follicular lymphoma
This trial tests a combination of a CAR T-cell therapy (Axicabtagene Ciloleucel) with radiation therapy for people with follicular lymphoma that has come back or not responded to multiple treatments. The goal is to see if adding radiation can make the CAR T cells work better.
Houston, TexasAges 18 years+ - NCT06047626Recruiting
Living well with lymphoma: a fatigue and nutrition study
This study tests if eating more fruits and vegetables can help reduce persistent fatigue in people with lymphoma. You will receive questionnaires by email to track your fatigue and diet over time.
Ann Arbor, MichiganAges 18 years+ - NCT06052826RecruitingPhase 2
Geriatric support to speed recovery after CAR-T for older adults
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
Duarte, CaliforniaAges 60 years+ - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,373 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.